Patents

We continually have internal projects running through our Research & Development program, some of which have been successfully patented over the years. These technologies have improved our processes and others' around the world. To make it easy for you to find one of our patents, we have provided them here for you to browse. Stay tuned to this page, as we always have R&D projects in the works.

  • Compositions and methods for producing genetically modified animals
    May 14, 2015 - WO 2015066768 A1 >

    Publication Date: May 14, 2015
    Inventor: Frank Koentgen
    Applicant: Ozgene Holdings Pty Ltd

    We are excited to announce Ozgene’s newest patent, “Compositions and methods for producing genetically modified animals”, or more commonly known as, goGermline. Simply put, goGermline only produces embryonic stem (ES) cell derived mice by eliminating competition with host embryos. goGermline provides for streamlined mouse generation, less waste, faster timelines, and improved animal welfare standards (the 3R’s – replace, reduce, refine). For Ozgene, this is the most influential patent so far and could change how the world creates future genetically modified animal models.

    Read More
  • Sequential Cloning System
    Jun 19, 2012 - US 8202727 B2 >

    Publication Date: Jun 19, 2012
    Inventors: Frank Koentgen
    Original Assignee: Ozgene Pty Ltd.

    Ozgene developed the Sequential Cloning System to maximise the efficiency of the cloning process. This has resulted in a reduction in our timeline to construct a targeting vector. In addition, it ensures that all modifications are reliably included and easily confirmed in the final construct. The Sequential Cloning System enables faster and more accurate construction of your gene targeting vector.

    Read More
  • Sequential Cloning System
    Feb 15, 2012 - EP 1882036 B1 >

    Publication Date: Feb 15, 2012
    Inventors: Frank Koentgen
    Applicant: Ozgene Pty Ltd.

    Ozgene developed the Sequential Cloning System to maximise the efficiency of the cloning process. This has resulted in a reduction in our timeline to construct a targeting vector. In addition, it ensures that all modifications are reliably included and easily confirmed in the final construct. The Sequential Cloning System enables faster and more accurate construction of your gene targeting vector.

    Read More
  • Sequential Cloning System
    Nov 23, 2006 - CA 2608636 A1 >

    Publication Date: Nov 23, 2006
    Inventors: Frank Koentgen
    Applicant: Frank Koentgen, Ozgene Pty Ltd.

    Ozgene developed the Sequential Cloning System to maximise the efficiency of the cloning process. This has resulted in a reduction in our timeline to construct a targeting vector. In addition, it ensures that all modifications are reliably included and easily confirmed in the final construct. The Sequential Cloning System enables faster and more accurate construction of your gene targeting vector.

    Read More
  • Methods and compositions for generating a genetically modified animal using lentiviral vectors
    Jul 24, 2003 - CA 2470527 A1 >

    Publication Date: Jul 24, 2003
    Inventors: Frank Koentgen, Ram Ramabhadran, John Wakefield
    Original Assignee: Ozgene Pty Ltd.

    Lentiviral transgenesis was one of Ozgene’s first patents. It was developed to reliably generate transgenics with up to 100% efficiency. It produced a large number of founders with multiple integrations. Lentiviral vectors could also be combined with RNAi technology in gene knockdown projects, overcoming the strain limitations of other technologies. The lentiviral patent is an important part of Ozgene’s success; however, it is no longer used as other technologies have advanced in its place.

    Read More
  • Methods and compositions for generating a genetically modified animal using lentiviral vectors
    Jul 24, 2003 - WO 2003059923 A2 >

    Publication Date: Jul 24, 2003
    Inventors: Ram Ramabhadran, Frank Koentgen, John Wakefield
    Applicant: Tranzyme, Inc., Ram Ramabhadran, Frank Koentgen, John Wakefield, Ozgene Pty. Ltd.

    Lentiviral transgenesis was one of Ozgene’s first patents. It was developed to reliably generate transgenics with up to 100% efficiency. It produced a large number of founders with multiple integrations. Lentiviral vectors could also be combined with RNAi technology in gene knockdown projects, overcoming the strain limitations of other technologies. The lentiviral patent is an important part of Ozgene’s success; however, it is no longer used as other technologies have advanced in its place.

    Read More
  • 1

Contact us

Contact us to discuss your mouse model requirements and the best solution for your project. We will provide you with an obligation free project design and quote.

Contact us now

Did you know?

Ozgene is the innovator in the C57BL/6 strain. Before founding Ozgene in 1999, Dr Frank Koentgen and Dr Gabi Suess were the first to generate and publish C57BL/6 KO mice in 1993.

Read publication

Proven Track Record

The team at Ozgene has over two decades of experience creating customised knockout and knock-in mice for pivotal medical research globally. Over 350 scientific publications are based on research using Ozgene mice.

Go to Publications

Global Client Base

Ozgene generates genetically customised mice for researchers around the world. Ozgene mice can be found in 31 different countries on 5 continents from small academic institutions to multinational pharmaceutical companies.

See Map

Lean Management

Ozgene is applying Lean Management principles to deliver the highest quality services and shortest lead times to our customers. The implementation of Lean Culture has already seen an improvement in our processes and timelines.

Read More